Bone Biologics Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Bone Biologics Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $1.07B | Apr 15, 2021 |
| FY2019 | Dec 31, 2019 | $1.07B | Mar 30, 2020 |
| FY2018 | Dec 31, 2018 | $1.07B | Mar 29, 2019 |
| FY2017 | Dec 31, 2017 | $1.07B | Apr 2, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.11M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($4.11M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($8.95M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | ($1.48M) | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | ($1.61M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($1.82M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | ($3.42M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($4.43M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($7.05M) | Mar 29, 2019 |
| FY2017 | Sep 30, 2017 | ($2.38M) | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.23M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($4.22M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($9.43M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | ($3.67M) | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | ($1.10M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($825.0K) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | ($2.45M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($2.79M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($2.63M) | Mar 29, 2019 |
| FY2017 | Sep 30, 2017 | ($1.13M) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.06M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $2.13M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $6.91M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $1.58M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $82.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $340.7K | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $1.10M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $104.5K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $1.42M | Mar 29, 2019 |
| FY2017 | Sep 30, 2017 | $248.4K | Apr 2, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.69M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($4.12M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($9.56M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | ($3.57M) | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | ($1.23M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($426.9K) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | ($3.25M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($4.10M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($3.33M) | Mar 29, 2019 |
| FY2017 | Sep 30, 2017 | ($2.40M) | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2015 | $504 | Mar 30, 2017 |
| FY2015 | Dec 31, 2014 | $11.9K | Mar 28, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.80M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $3.86M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $3.74M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $8.50M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $6.68M | Mar 30, 2023 |
| FY2020 | Dec 31, 2020 | $0 | Apr 15, 2021 |
| FY2020 | Dec 31, 2019 | $30.8K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $1.04M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $795.7K | Mar 29, 2019 |
| FY2017 | Sep 30, 2017 | $1.67M | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $418.6K | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $377.7K | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $831.4K | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $2.55M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $99.9K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $13.69M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $11.90M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $9.64M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $9.19M | Mar 29, 2019 |
| FY2017 | Sep 30, 2017 | $11.85M | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.38M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $3.48M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $2.91M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $5.95M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $6.58M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | ($13.69M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | ($11.87M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2018 | ($8.60M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2017 | ($8.40M) | Mar 30, 2020 |
| FY2017 | Sep 30, 2017 | ($10.18M) | Apr 2, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($88.13M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($85.02M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($80.91M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | ($71.96M) | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | ($70.48M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($68.86M) | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | ($67.04M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($63.62M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($59.19M) | Mar 29, 2019 |
| FY2017 | Sep 30, 2017 | $56.42M | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $6.68M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $24.1K | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $955.4K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $690.3K | Mar 29, 2019 |
| FY2017 | Sep 30, 2017 | $1.62M | Apr 2, 2018 |
| FY2017 | Jun 30, 2017 | $783.0K | Apr 2, 2018 |
| FY2017 | Mar 31, 2017 | $1.61M | Apr 2, 2018 |
| FY2018 | Dec 31, 2016 | $620.4K | Mar 29, 2019 |
| FY2017 | Sep 30, 2016 | $688.2K | Apr 2, 2018 |
| FY2017 | Jun 30, 2016 | $2.19M | Apr 2, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | (28) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | (34) | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | (31) | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2017 | Jun 30, 2017 | 0 | Apr 2, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | (28) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | (34) | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | (31) | Feb 21, 2024 |
| FY2017 | Jun 30, 2017 | 0 | Apr 2, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.80M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 492,417 | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | 534,238 | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | 63,820 | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | 10.35M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 12.27M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | 30.68M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | 26.45M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 4.33M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | 38.83M | Apr 2, 2018 |